Aadi Bioscience (AADI) Stock Forecast, Price Target & Predictions
AADI Stock Forecast
Aadi Bioscience stock forecast is as follows: an average price target of $1.63 (represents a -26.58% downside from AADI’s last price of $2.22) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
AADI Price Target
The average price target for Aadi Bioscience (AADI) is $1.63 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $1.75 to $1.50. This represents a potential -26.58% downside from AADI's last price of $2.22.
AADI Analyst Ratings
According to 4 Wall Street analysts, Aadi Bioscience's rating consensus is 'Hold'. The analyst rating breakdown for AADI stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 4 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aadi Bioscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Joseph Catanzaro | Piper Sandler | $1.75 | $1.75 | - | -21.17% |
| Aug 21, 2024 | Roger Song | Jefferies | $1.50 | $1.55 | -3.23% | -32.43% |
The latest Aadi Bioscience stock forecast, released on Aug 27, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $1.75, which represents a 0.00% decrease from the stock price at the time of the forecast ($1.75), and a -21.17% decrease from AADI last price ($2.22).
Aadi Bioscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $1.63 | $1.63 |
| Last Closing Price | $2.22 | $2.22 | $2.22 |
| Upside/Downside | -100.00% | -26.58% | -26.58% |
In the current month, the average price target of Aadi Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aadi Bioscience's last price of $2.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Piper Sandler | - | Neutral | Downgrade |
| Aug 21, 2024 | Jefferies | Buy | Hold | Downgrade |
| Aug 21, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Aug 21, 2024 | Cowen & Co. | - | Hold | Downgrade |
| May 09, 2024 | Jefferies | Buy | Buy | Hold |
Aadi Bioscience's last stock rating was published by Piper Sandler on Aug 27, 2024. The company Downgrade its AADI rating from "null" to "Neutral".
Aadi Bioscience Financial Forecast
Aadi Bioscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $5.96M | $6.20M | $5.87M | $5.23M | $4.25M | $3.44M | $2.31M | $1.00M | - | $14.00M | $15.00M |
| Avg Forecast | $7.34M | $7.30M | $6.87M | $6.63M | $7.27M | $6.59M | $6.19M | $6.47M | $6.29M | $6.62M | $6.20M | $5.48M | $4.82M | $3.74M | $2.75M | $375.75K | $45.00K | $78.75K | $2.00M | $15.00M |
| High Forecast | $7.88M | $7.83M | $7.37M | $7.33M | $7.60M | $6.60M | $6.64M | $6.94M | $6.42M | $6.62M | $6.65M | $5.88M | $5.17M | $3.74M | $2.75M | $375.75K | $45.00K | $78.75K | $2.00M | $15.00M |
| Low Forecast | $6.88M | $6.84M | $6.43M | $5.94M | $7.00M | $6.59M | $5.80M | $6.06M | $6.14M | $6.62M | $5.80M | $5.13M | $4.51M | $3.74M | $2.75M | $375.75K | $45.00K | $78.75K | $2.00M | $15.00M |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 1.00% | 1.07% | 1.08% | 1.14% | 1.25% | 6.14% | 22.22% | - | 7.00% | 1.00% |
Aadi Bioscience's average Quarter revenue forecast for Dec 23 based on 4 analysts is $6.29M, with a low forecast of $6.14M, and a high forecast of $6.42M. AADI's average Quarter revenue forecast represents a 5.60% increase compared to the company's last Quarter revenue of $5.96M (Sep 23).
Aadi Bioscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-17.85M | $-19.55M | $-15.16M | $-13.86M | $-14.40M | $-14.48M | $-13.72M | $-15.86M | $-86.93M | $-4.70M | $9.29M |
| Avg Forecast | $-6.14M | $-6.10M | $-5.74M | $-5.54M | $-6.07M | $-5.51M | $-5.17M | $-5.41M | $-5.26M | $-5.53M | $-5.18M | $-4.58M | $-4.03M | $-3.13M | $-2.31M | $-14.69M | $-37.70K | $-65.98K | $-1.68M | $-12.57M |
| High Forecast | $-5.75M | $-5.71M | $-5.37M | $-4.96M | $-5.85M | $-5.50M | $-4.84M | $-5.06M | $-5.13M | $-5.53M | $-4.85M | $-4.29M | $-3.77M | $-3.13M | $-2.31M | $-11.75M | $-37.70K | $-65.98K | $-1.68M | $-12.57M |
| Low Forecast | $-6.58M | $-6.54M | $-6.15M | $-6.12M | $-6.35M | $-5.52M | $-5.55M | $-5.80M | $-5.36M | $-5.53M | $-5.55M | $-4.91M | $-4.32M | $-3.13M | $-2.31M | $-17.63M | $-37.70K | $-65.98K | $-1.68M | $-12.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.23% | 3.77% | 3.31% | 3.44% | 4.60% | 6.28% | 0.93% | 420.67% | 1317.41% | 2.81% | -0.74% |
2 analysts predict AADI's average Quarter EBITDA for Dec 20 to be $-1.68M, with a high of $-1.68M and a low of $-1.68M. This is -118.04% lower than Aadi Bioscience's previous annual EBITDA (Jun 20) of $9.29M.
Aadi Bioscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-16.30M | $-17.97M | $-13.68M | $-13.91M | $-13.32M | $-18.27M | $-13.90M | $-16.05M | $-87.09M | $-4.72M | $9.28M |
| Avg Forecast | $-9.82M | $-8.29M | $-8.02M | $-7.13M | $-8.38M | $-12.37M | $-18.66M | $-16.87M | $-17.52M | $-19.58M | $-16.82M | $-15.79M | $-18.05M | $-20.04M | $-20.26M | $-14.83M | $-22.26M | $-15.60M | $-54.03M | $109.39M |
| High Forecast | $-9.02M | $-7.61M | $-7.36M | $-7.03M | $-6.48M | $-11.35M | $-17.12M | $-15.49M | $-16.22M | $-17.97M | $-15.44M | $-14.49M | $-16.57M | $-20.04M | $-20.26M | $-11.87M | $-22.26M | $-15.60M | $-54.03M | $109.39M |
| Low Forecast | $-10.75M | $-9.08M | $-8.78M | $-7.24M | $-10.67M | $-13.54M | $-20.42M | $-18.47M | $-19.09M | $-21.43M | $-18.41M | $-17.28M | $-19.75M | $-20.04M | $-20.26M | $-17.80M | $-22.26M | $-15.60M | $-54.03M | $109.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.83% | 1.07% | 0.87% | 0.77% | 0.66% | 0.90% | 0.94% | 0.72% | 5.58% | 0.09% | 0.08% |
Aadi Bioscience's average Quarter net income forecast for Dec 20 is $-54.03M, with a range of $-54.03M to $-54.03M. AADI's average Quarter net income forecast represents a -682.43% decrease compared to the company's last Quarter net income of $9.28M (Jun 20).
Aadi Bioscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $11.22M | $11.78M | $11.21M | $11.11M | $9.91M | $10.01M | $9.15M | $9.72M | $7.40M | $2.41M | $2.20M |
| Avg Forecast | $52.95M | $52.64M | $49.52M | $47.83M | $52.41M | $47.56M | $44.64M | $46.66M | $45.38M | $47.74M | $44.69M | $39.52M | $34.76M | $26.95M | $19.85M | $2.71M | $324.50K | $567.88K | $14.42M | $108.17M |
| High Forecast | $56.80M | $56.46M | $53.11M | $52.83M | $54.79M | $47.62M | $47.88M | $50.04M | $46.29M | $47.74M | $47.93M | $42.39M | $37.28M | $26.95M | $19.85M | $2.71M | $324.50K | $567.88K | $14.42M | $108.17M |
| Low Forecast | $49.60M | $49.31M | $46.38M | $42.84M | $50.46M | $47.49M | $41.81M | $43.70M | $44.25M | $47.73M | $41.86M | $37.02M | $32.56M | $26.95M | $19.85M | $2.71M | $324.50K | $567.88K | $14.42M | $108.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.26% | 0.28% | 0.32% | 0.37% | 0.50% | 3.38% | 29.95% | 13.03% | 0.17% | 0.02% |
Aadi Bioscience's average Quarter SG&A projection for Dec 23 is $45.38M, based on 4 Wall Street analysts, with a range of $44.25M to $46.29M. The forecast indicates a 304.39% rise compared to AADI last annual SG&A of $11.22M (Sep 23).
Aadi Bioscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.51 | $-0.52 | $-0.63 | $-0.87 | $-0.66 | $-0.77 | $-9.17 | $-1.50 | $3.40 |
| Avg Forecast | $-0.36 | $-0.31 | $-0.30 | $-0.26 | $-0.31 | $-0.46 | $-0.69 | $-0.62 | $-0.65 | $-0.72 | $-0.62 | $-0.58 | $-0.67 | $-0.74 | $-0.75 | $-0.70 | $-0.82 | $-0.58 | $-2.00 | $4.05 |
| High Forecast | $-0.33 | $-0.28 | $-0.27 | $-0.26 | $-0.24 | $-0.42 | $-0.63 | $-0.57 | $-0.60 | $-0.66 | $-0.57 | $-0.54 | $-0.61 | $-0.74 | $-0.75 | $-0.70 | $-0.82 | $-0.58 | $-2.00 | $4.05 |
| Low Forecast | $-0.40 | $-0.34 | $-0.32 | $-0.27 | $-0.39 | $-0.50 | $-0.76 | $-0.68 | $-0.71 | $-0.79 | $-0.68 | $-0.64 | $-0.73 | $-0.74 | $-0.75 | $-0.70 | $-0.82 | $-0.58 | $-2.00 | $4.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.87% | 0.78% | 0.85% | 1.16% | 0.94% | 0.93% | 15.88% | 0.75% | 0.84% |
According to 2 Wall Street analysts, Aadi Bioscience's projected average Quarter EPS for Dec 20 is $-2.00, with a low estimate of $-2.00 and a high estimate of $-2.00. This represents a -158.83% decrease compared to AADI previous annual EPS of $3.40 (Jun 20).
Aadi Bioscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
| AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ACRV | Acrivon Therapeutics | $6.50 | $21.83 | 235.85% | Buy |
| ARVN | Arvinas | $22.69 | $71.00 | 212.91% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| ANAB | AnaptysBio | $20.31 | $52.00 | 156.03% | Buy |
| ERAS | Erasca | $2.64 | $6.50 | 146.21% | Buy |
| ADAG | Adagene | $2.09 | $5.00 | 139.23% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| RARE | Ultragenyx Pharmaceutical | $46.40 | $106.93 | 130.45% | Buy |
| DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
| KURA | Kura Oncology | $15.91 | $26.00 | 63.42% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.07 | $70.14 | 25.09% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| AADI | Aadi Bioscience | $2.22 | $1.63 | -26.58% | Hold |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |